Addex Therapeutics Valuation
Is ADXN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ADXN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ADXN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ADXN's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ADXN?
Key metric: As ADXN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ADXN's PS Ratio? | |
|---|---|
| PS Ratio | 9.4x |
| Sales | CHF 592.36k |
| Market Cap | CHF 5.56m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.8x |
| Enterprise Value/EBITDA | -0.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ADXN's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.2x | ||
SPEX Spexis | 5.7x | n/a | CHF 3.4m |
MOLN Molecular Partners | 29.8x | 57.8% | CHF 178.8m |
RLF Relief Therapeutics Holding | 7.3x | n/a | CHF 62.7m |
IDIA Idorsia | 2x | 53.8% | CHF 145.8m |
ADXN Addex Therapeutics | 9.4x | 44.2% | CHF 5.6m |
Price-To-Sales vs Peers: ADXN is good value based on its Price-To-Sales Ratio (9.4x) compared to the peer average (11.2x).
Price to Sales Ratio vs Industry
How does ADXN's PS Ratio compare vs other companies in the European Biotechs Industry?
| 38 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 38 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: ADXN is expensive based on its Price-To-Sales Ratio (9.4x) compared to the European Biotechs industry average (7.9x).
Price to Sales Ratio vs Fair Ratio
What is ADXN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 9.4x |
| Fair PS Ratio | 0.03x |
Price-To-Sales vs Fair Ratio: ADXN is expensive based on its Price-To-Sales Ratio (9.4x) compared to the estimated Fair Price-To-Sales Ratio (0x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Gerresheimer
€2.6b
Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.
GXI
€75.60
7D
0%
1Y
0%
Roche Holding
CHF 204.3b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.
ROG
CHF 254.30
7D
-0.6%
1Y
6.5%
Cosmo Pharmaceuticals
CHF 1.0b
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
COPN
CHF 62.80
7D
-1.3%
1Y
58.4%